Agilent: Back To The Lab - [Business Breakdowns, EP.223]

Garage-to-Lab Legacy

Agilent traces its roots to 1938 when Bill Hewlett and Dave Packard built their first testing instrument for Disney's Fantasia, evolving through HP's testing and measurement division before spinning off in 1999.

Pure-Play Transformation

The 2014 spin-off of Keysight Technologies (40% of sales) divested cyclical electronic testing to create a focused life sciences company serving 285,000 labs across 110 countries.

Recurring Revenue Engine

Roughly one-third of revenue comes from $100,000 instruments with 6-10 year lifespans, while two-thirds comes from consumables (columns replaced every ~2,000 samples) and services, creating $100,000 in follow-on spend per unit.

Growing Service Attachments

Service contract attach rates have steadily climbed from high-20% to low-30% over five years, with Agilent employing 4,000 technicians (75% with chemistry degrees) who perform 2,500 on-site calls daily.

Regulatory Lock-In

Quality control processes are often written into FDA drug approvals specifying exact Agilent instruments and consumables, making switching expensive and risky given the unquantifiable cost of contamination failures.

Dominant Market Share

Agilent commands approximately two-thirds of the global gas chromatography market and one-third of liquid chromatography, competing primarily with Waters (pharma-focused) and Thermo Fisher (broad catalog).

Stable Duopoly Dynamics

Decades-long customer relationships and high switching costs create entrenched market shares where competitors might gain only a single percentage point after years of innovation.

Consistent Compounder

Since the 2014 Keysight spin-off, Agilent has delivered 5% organic revenue growth and 13% annual EPS growth, with low-single-digit pricing power reflecting long-term relationship prioritization.

Post-COVID Normalization

The company is emerging from a pharma inventory correction following pandemic-era over-investment in lab capacity, while China (18% of sales) shows signs of recovery from government grant cycles.